Scholars Central

Conference abstractPublished 25 Sep 2014

Production of biosimilars in developing countries: Challenges and opportunities: SEDICO case Study

Authors: Wael Ebied

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Control of chronic diseases is a major challenge for public health systems in developed and developing countries. However, high cost limited their use in developing countries. The expiration of the patents on many Biopharmaceuticals such as insulin, human growth hormone and erythropoietin opened the door for licensing these products as biosimilars. This might contribute to increased access to these medicines at an affordable price. Unlike traditional generic pharmaceuticals, biosimilars (also called ?follow-on biopharmaceuticals? in the USA) aim to copy a complex recombinant, three dimensional protein structures with high molecular weight. According to the guidelines of the EMEA, extensive comparability testing will be required to demonstrate that the biosimilars has a comparable profile in terms of quality, safety and efficacy as the reference product. The pharmacologic properties of biological medicines depend on the production and purification processes. Therefore, Biosimilars differ from generic drugs. Only if their quality, efficacy, and safety are clearly documented biosimilars may be chosen because of their lower costs. In a few years ago, SEDICO, ?South Egypt Drug Industries Company?, an Egyptian pharmaceutical company, biotech products were available in the Egyptian market such as ?Insulin, erythropoietin, streptokinase, angiokinase, follicle-stimulating hormone (FSH), aprotinin, filgrastim (G-CSF) and somatropin (Growth Hormone)?. The results confirmed that SEDICO biosimilars can compete with the originator products in the Egyptian and some export markets with high quality challenge and lower cost opportunity. The biosimilars of SEDICO qualify with respect to their authenticity, purity, quality, safety, efficacy, and immunogenicity. The primary reason for prescribing a biosimilar in developing countries is its lower price. SEDICO? recombinant proteins have been established in clinical use. SEDICO succeeded to supply biosimilars with accepted quality and with affordable prices. SEDICO biosimilars were examined for its quality by analytical methods. The analytical tests to demonstrate comparability and similarity of EPO as a biosimilar product to a reference drug with respect to protein content, activity, physiochemical integrity and stability, as well as immunogenicity are discussed. Clinical studies and post-authorization pharmacovigilance will provide essential evidence for product quality. SEDICO Biotech products are clinically tested and trusted in multicenter studies performed in many universities and medical research units.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Wael Ebied”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels